Latest news with #Biovet
The Hindu
14-05-2025
- Health
- The Hindu
Andhra Pradesh Chief Minister Chandrababu Naidu launches vaccine for lumpy skin disease in animals
Andhra Pradesh Chief MinisterN. Chandrababu Naidu launched a vaccine, Biolumpivaxin, developed by Biovet, aimed at improving disease surveillance in livestock to protect them from lumpy skin disease (LSD), at the Livestock Prosperity Conclave organised in Vijayawada on May 14, Wednesday. Applauding Biovet, an animal vaccine maker and a subsidiary of Bharat Biotech located at Malur in Karnataka, Mr. Naidu said the launch of the vaccine was an important step towards eradicating LSD, and measures should be taken to ensure effective rollout of the vaccine, which could contribute to the State's targeted 20% livestock growth trajectory and promote the long-term sustainability of the dairy industry, a press release from the company said. The quality and efficacy of the vaccine, developed in collaboration with the Indian Council of Agricultural Research (ICAR), was tested at ICAR-Indian Veterinary Research Institute (IVRI) and the ICAR-National Research Centre on Equines (ICAR-NRCE), the release added. The company received the Central Drug Standards Control Organisation (CDSCO) licence for the vaccine in February. Biolumpivaxin is also the world's first 'Differentiating Infected from Vaccinated Animals' (DIVA) marker vaccine. Such marker vaccines are designed to produce an immune response distinct from that of natural infection. The company said the vaccine was given once in a year to cattle and buffaloes of all ages. It said it could produce 500 million doses from its production facilities in Bengaluru, ensuring sustainable supplies. LSD is a transboundary animal disease, characterised by development of skin nodules across the body, fever, swollen lymph nodes, decreased milk yield and difficulty in movement. LSD virus transmission is largely attributed to vector bites, with mosquitoes, ticks, and other biting insects playing an essential role. The company said vaccination proved to be the most effective strategy for controlling LSD virus. It might take 3 to 4 weeks to mount desired immunity in the vaccinated animals. Hence, advance vaccination to be done as a preventive measure to protect dairy cattle and buffaloes from LSD. Expressing gratitude to the Chief Minister, Krishna Ella, Founder, Biovet, and Executive Chairman of Bharat Biotech, said livestock, alongside human resources, represented one of the nation's greatest assets, contributing significantly to the Indian economy and that they carried a responsibility to protect this sector and ensure the well-being of the dairy industry.
Deccan Herald
14-05-2025
- Health
- Deccan Herald
Biolumpivaxin: Chandrababu Naidu launches new vaccine against lumpy skin disease in Vijayawada
Hyderabad: Andhra Pradesh Chief Minister N Chandrababu Naidu launched indigenous Lumpy Skin Disease (LSD) vaccine Biolumpivaxin in Vijayawada on Wednesday. Developed by Biovet, a subsidiary of Bharat Biotech, this CDSCO-approved vaccine is the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, enhancing disease surveillance capabilities to protect Private Ltd, an emerging animal health vaccine producing company located at Malur, Karnataka currently has a world class Foot and Mouth Disease vaccine production facility at the Malur KIADS near Bangalore and is committed to produce animal health care products including veterinary biologicals, bio-vaccines and other related products for large animals, poultry and pet LSD vaccine requires only a single annual dose for cattle and buffaloes of all ages. According to national statistics from the Animal Husbandry and Dairy Ministry, India has experienced two major LSD outbreaks first in 2019 and again in 2022 resulting in approximately 200,000 cattle more lost milk production capabilities due to the disease. When infected with LSD, livestock suffer from high fever and painful skin nodules that can prove fatal and contaminate milk. The infection significantly reduces milk yield, posing a serious threat to large-scale dairies and disrupting the broader milk supply new study, scientists decipher virus behind lumpy skin disease the lumpy skin disease vaccine Biolumpivaxin Naidu remarked, it is heartening to note the availability of world class made in India vaccine. He emphasised that all viable measures should be taken earnestly to ensure the effective rollout of the vaccine, which not only can contribute to the state's targeted 20% livestock growth trajectory but also promote the long-term sustainability of the dairy that DIVA Marker LSD vaccine as an important step toward eradicating Lumpy disease, Biovet, founder and Executive Chairman of Bharat Biotech, Dr. Krishna Ella, said , 'We are truly honoured. Livestock, alongside our human resources, represents one of the nation's greatest assets, contributing significantly to our economy and overall prosperity. We carry a deep responsibility to protect this sector, ensure the well-being of the dairy industry, and advance the nation's Atmanirbhar Bharat vision.'BIOLUMPIVAXIN is a novel indigenous live-attenuated marker vaccine developed using the LSD virus/Ranchi/2019 vaccine strain from Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE), Hisar, in collaboration with quality, safety, and efficacy of Biolumpivaxin have been extensively tested at Indian Council of Agriculture Research-Indian Veterinary Research Institute (IVRI) and the Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE) ensuring it meets the highest global standards. The vaccine also enables serological differentiation between naturally infected and vaccinated animals with the DIVA can produce 500 million doses of the vaccine from its production facilities in Bengaluru, ensuring sustainable Ministry of Animal Husbandry and Dairying, Fisheries, the livestock sector has grown around 10% in the nine years and contributed to total agriculture and allied sector to over 30% from 24.36%.LSD virus transmission is largely attributed to vector bites, with mosquitoes, ticks, and other biting insects playing an essential the 2022 LSD outbreak in India, morbidity rates reached up to 80% with case fatality rates as high as 67%, across states such as Gujarat, Rajasthan, Maharashtra, Uttar Pradesh, Punjab, and Jammu & Kashmir. This caused an estimated economic loss of over ₹18,337.76 crore and a 26% decline in milk production, significantly harming the dairy industry and the rural economy.
Hindustan Times
14-05-2025
- Health
- Hindustan Times
Biolumpivaxin: Bharat Biotech launches new vaccine against lumpy skin disease
Andhra Pradesh chief minister N Chandrababu Naidu on Wednesday launched Bharat Biotech group company Biovet's new vaccine against the lumpy skin disease (LSD) in dairy cattle and buffaloes, the company announed in a statement. The vaccine— Biolumpivaxin— was launched during the Livestock Prosperity Conclave in Vijayawada. 'All viable measures should be taken earnestly to ensure the effective rollout of the vaccine, which not only can contribute to the state's targeted 20% livestock growth trajectory but also promote the long-term sustainability of the dairy industry…,' said Naidu at the launch. According to national statistics by the animal husbandry, dairy ministry, there have been two major outbreaks of LSD in India, the first in 2019 and the second in 2022. During these outbreaks, approximately 200,000 cattle have died, and millions more cattle have lost their milk production capabilities due to Lumpy Skin Disease (LSD). Also Read: New vaccine to prevent lumpy skin disease in cattle gets govt approval In February, this year, the company received approval from the national drugs regulator— Central Drugs Standard Control Organisation (CDSCO) to market the vaccine. Biolumpivaxin, is the world's first Differentiating Infected from Vaccinated Animals (DIVA) marker vaccine, which will help in disease surveillance as it means the experts will be able to distinguish between vaccinated and naturally infected dairy cattle. It is a live-attenuated marker vaccine developed using the LSD virus/Ranchi/2019 vaccine strain from Indian Council of Agriculture Research-National Research Centre on Equines (ICAR-NRCE), Hisar, in collaboration with Biovet. The vaccine is a single vaccination regimen given once in a year to cattle and buffaloes of all ages. The presentation is in multi dose vials from 25 doses up to a maximum of 100 doses per vial and the vaccine is stable at 2-8° C storage temperature. Biovet can produce 500 million doses of the vaccine from its production facilities in Bengaluru, ensuring sustainable supplies, said the company. 'Livestock, alongside our human resources, represents one of the nation's greatest assets, contributing significantly to our economy and overall prosperity. We carry a deep responsibility to protect this sector, ensure the well-being of the dairy industry, and advance the nation's Atmanirbhar Bharat vision,' said Krishna Ella, founder, Biovet, and executive chairman, Bharat Biotech, in a statement.
